Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial

Study limitation reported by the research below: “The 'practice changing' flag is applied because this large RCT provides direct evidence against routine use of these drugs for long COVID fatigue — a negative/null practice-changing finding.”